Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132118 · ClinicalTrials.gov registry record · Phase 3
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
A Phase 3 study of Rheumatoid Arthritis and Insulin Resistance, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01132118 is a Phase 3 study of Rheumatoid Arthritis and Insulin Resistance that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01132118, a Phase 3 study of Rheumatoid Arthritis and Insulin Resistance, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that HCQ improves insulin sensitivity. The investigators will also use data from the trial to identify determinants of insulin resistance in RA. The investigators hypothesize that RA will be associated with an increased risk of insulin resistance and that independent risk factors for increased insulin resistance in RA include higher BMI, elevated acute phase reactants, greater fat to muscle ratio, and less physical activity.
Conditions Studied
Interventions
- DRUG Hydroxychloroquine
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01132118
The ClinicalTrials.gov registry entry for NCT01132118 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Hydroxychloroquine is the first listed.
NCT01132118 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01132118 about?
NCT01132118 is a clinical study titled "Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis". The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that HCQ improves insulin...
What is the current status of trial NCT01132118?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2010-06. Estimated completion is 2012-06.
What conditions does trial NCT01132118 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Insulin Resistance.
What interventions are being tested in trial NCT01132118?
The interventions under investigation include: Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01132118?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01132118 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.